Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Aclaris Therapeutics Reports Phase 2 Trial Failure; Pivot to Oral ITK Inhibitors Announced

Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug for moderate-to-severe atopic dermatitis failed to reach its primary and secondary endpoints. The company will now shift its strategic development focus toward its oral ITK inhibitors and bispecific antibody candidates.

Tablets, medicine, supplement, vitamin. Stock photo illustrating Aclaris Therapeutics' other story.
Aclaris Therapeutics, Inc. · Healthcare · Photo: HeungSoon / Pixabay

Key highlights

  • Phase 2 ADMIRATION trial of bosakitug (ATI-045) did not achieve its primary endpoint of EASI score change at Week 24
  • Company confirmed robust target engagement and biomarker downregulation despite the clinical endpoint failure
  • Initiated Phase 2b ALPHA trial for modzatinib in lichen planus with results expected in late 2027
  • Plan to file an Investigational New Drug application for oral ITK inhibitor ATI-9494 in Q4 2026
  • Scheduled initiation of a Phase 2b trial for bispecific antibody ATI-052 in eosinophilic esophagitis for Q1 2027

Phase 2 Clinical Trial Outcome

Aclaris Therapeutics reported that its Phase 2 ADMIRATION trial, which evaluated the humanized anti-TSLP monoclonal antibody bosakitug for moderate-to-severe atopic dermatitis, did not achieve its primary or secondary endpoints. The study failed to show a statistically significant percent change from baseline in the Eczema Area and Severity Index (EASI) score at Week 24. While clinical endpoints were not met, pharmacodynamic data confirmed robust target engagement of TSLP and downregulation of biomarkers related to immune activation, including Th1, Th2, and Th17. The candidate was generally well tolerated, but the company will not proceed with current development plans for this specific indication.

Strategic Pivot to ITK Inhibitor Portfolio

  • Initiation of the randomized, double-blind Phase 2b ALPHA trial for modzatinib in moderate-to-severe lichen planus
  • Expectation of top-line results from the oral erosive lichen planus cohort of the ALPHA trial in the second half of 2027
  • Completion of IND-enabling studies for ATI-9494, an oral ITK inhibitor, with a regulatory filing expected in Q4 2026
  • Planned Phase 1 clinical program for ATI-9494 to include single and multiple ascending doses followed by a proof-of-concept portion
  • Intent to launch a Phase 2b trial for ATI-052 targeting eosinophilic esophagitis in the first quarter of 2027

Management Perspective

“We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone.”

Dr. Neal Walker, Chief Executive Officer, Aclaris Therapeutics

Business and Financial Context

Aclaris Therapeutics is a Wayne, Pennsylvania-based clinical-stage biopharmaceutical firm focused on immuno-inflammatory diseases. With a market capitalization of $621.76 million, the company operates as a research-intensive entity, evidenced by its annual revenue of $7.83 million against ongoing clinical expenditures. The shift toward oral kinase inhibitors like modzatinib and ATI-9494 represents a transition toward differentiated mechanisms of action that may offer advantages over traditional biologics. Shareholders and analysts will likely focus on the series of clinical and regulatory milestones scheduled throughout 2027 as the primary drivers of future company valuation.

Aclaris Therapeutics, Inc. share price · last month
Line chart of Aclaris Therapeutics, Inc.'s share price over the last month, from $3.48 on 19 Oct → $3.60 on 16 Nov; our story on 16 Nov at $3.92.

Down 8.0% since our story on 16 Nov: $3.92 when we broke it → $3.60 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$3.48
20 Oct$3.77
21 Oct$3.81
22 Oct$3.83
23 Oct$3.75
26 Oct$3.79
27 Oct$3.79
28 Oct$3.96
29 Oct$3.99
30 Oct$3.97
2 Nov$3.80
3 Nov$3.74
4 Nov$3.68
5 Nov$3.61
6 Nov$3.90
9 Nov$4.24
10 Nov$4.15
11 Nov$4.34
12 Nov$4.00
13 Nov$3.92
16 Nov$3.60

Management commentary

“We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone.”

Dr. Neal Walker, Chief Executive Officer
Aclaris Therapeutics, Inc. · financial snapshot
Share price$3.92
Market cap$622M
Revenue (annual)$8M
1-month price change+15.98%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Aclaris Therapeutics, Inc. announcing top-line results from its Phase 2 ADMIRATION trial and subsequent pipeline updates.

Read the filing ↗
All Aclaris Therapeutics, Inc. filings and newsView all →

Track Aclaris Therapeutics, Inc. live

Get the next Aclaris Therapeutics, Inc. SEC filing seconds after it lands.

More from Aclaris Therapeutics, Inc.

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.